Biogen Profit Rises With Tecfidera Sales Boost

Biogen Idec Inc., a maker of multiple sclerosis drugs, reported a 27 percent jump in second-quarter profit and raised its 2013 forecast after its recently approved pill Tecfidera helped boost sales.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.